Ovarian carcinoma
- First-line therapy in combination with a platinum compound for the treatment of advanced metastatic carcinoma of the ovary.
- Second-line therapy for the treatment of advanced metastatic carcinoma of the ovary.
Breast carcinoma
- Adjuvant treatment of node-positive breast cancer administered sequentially to standard combination therapy.
- Therapy after relapse within 6 months of adjuvant therapy. Prior therapy should have included an anthracycline unless clinically contraindicated.
- Second-line therapy after failure of combination chemotherapy for metastatic disease. Prior therapy should have included an anthracycline unless clinically contraindicated.
- For the treatment of advanced or metastatic breast cancer in combination with trastuzumab in patients who over express HER-2 at 3+ level as determined by immunohistochemistry or FISH +.
Non-small cell lung carcinoma (NSCLC)
First-line therapy in combination with a platinum compound for the treatment of non-small cell carcinoma of the lung in patients who are not candidates for potentially curative surgery and / or radiation therapy.
Kaposi’s sarcoma
Second-line treatment of AIDS-related Kaposi’s sarcoma
Compositions :
Each mL contain Paclitaxel 6 mg
Storage Condition :
Store below 30°C
